Home » Topics » BioWorld Science

BioWorld Science
RSS

P38 targeting reverses immunosuppressive tumor microenvironment in metastatic breast cancer

Dec. 21, 2021

Novel XO inhibitors show efficacy in acute hyperuricemia rat model

Dec. 21, 2021

Mouse model of metaplastic breast cancer with conditional overexpression of TRIM24

Dec. 21, 2021

MCC-1734 inhibits cancer cells with different resistance mechanisms

Dec. 21, 2021

IpY.20 targets p27Kip1 to evade breast cancer resistance driven by CDK4 and CDK2

Dec. 21, 2021

CLIP-170S confers resistance to taxane-based therapy in gastric cancer

Dec. 21, 2021

JAK inhibitors divulged by Jiangsu Hansoh Pharmaceutical, Shanghai Hansoh Biomedical

Dec. 21, 2021

Biopolar Hongye presents new Janus kinase inhibitors

Dec. 21, 2021

GTPase KRAS mutant inhibitors patented by Genfleet Therapeutics

Dec. 21, 2021

Researchers unveil ACOT13, PTGER2 as candidate genes of autosomal dominant polycystic kidney disease

Dec. 21, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...